Long before anyone isolated apigenin in a laboratory, people were drinking it, unknowingly, in cups of chamomile tea. The compound’s story is really two stories: a centuries-long tradition of botanical use, and a much more recent chapter of biochemical research that explained why the tradition worked as well as it seemed to.
Disclosure: ApigeninHub is a participant in the Amazon Services LLC Associates Program. Some links in this article are affiliate links, and we may earn a commission on qualifying purchases at no extra cost to you.
Traditional Use of Chamomile
Chamomile has a long record of traditional use as a calming and digestive herbal remedy. Modern reviews describe chamomile tea, brewed from dried flower heads, as one of the most popular single-ingredient herbal teas with a long record of traditional medicinal use, and identify apigenin among the principal flavonoids of the flowers.[1]
Parsley and celery, the other major dietary sources of apigenin, have similarly long culinary and folk-medicine histories, though they were valued more as flavoring herbs and digestive aids than as calming agents specifically.
Isolation and Early Chemistry
Apigenin was first isolated and characterized as a distinct chemical compound in the 19th century as chemists began systematically cataloging the flavonoid compounds present in common plants. It was identified as one of the simpler flavones structurally, which later made it easier to study in detail compared to more complex polyphenols.
Research note: A systematic review of oral chamomile (mostly extracts and teas, not pure apigenin) found that 9 of 10 included clinical trials concluded it reduced anxiety [8].
For much of the 20th century, apigenin remained a relatively obscure entry in plant chemistry literature, studied mostly by botanists and food chemists cataloging plant compounds rather than by pharmacologists.
The Shift Toward Pharmacological Research
Interest in apigenin as a pharmacologically active compound accelerated from the 1990s onward, as researchers began systematically screening dietary flavonoids for receptor activity and anticancer potential. Early studies of apigenin’s interaction with GABA-A receptors are often cited as a possible explanation for chamomile’s traditional reputation as a calming beverage, although they do not show that apigenin is responsible [2][3][4]. Those studies are specific, and they do not fully agree. A 1995 fractionation of an aqueous chamomile extract identified apigenin as a central benzodiazepine-receptor ligand with anxiolytic activity in mice;[2] a 2000 study confirmed the same binding but found apigenin reduced GABA-activated chloride currents and produced no anxiolytic, muscle-relaxant or anticonvulsant effect in rats.[3] The receptor interaction is real; its direction of effect is still contested.
Around the same period, oncology researchers began screening apigenin against various cancer cell lines, part of a broader wave of interest in dietary flavonoids as potential chemopreventive compounds. This research built momentum through the 2000s and 2010s and remains an active area of preclinical study today.
Modern Popularization
Apigenin’s recent visibility outside academic circles owes a lot to the biohacking and sleep-optimization communities, particularly after it was discussed publicly as part of sleep-focused supplement protocols. This exposure introduced apigenin to a much broader audience than the relatively niche flavonoid-research community that had studied it for decades.
That popularization has been a double-edged sword: it has driven legitimate interest and consumer access to a well-studied natural compound, but it has also produced a wave of overstated marketing claims that outpace what the underlying research, still mostly preclinical, can actually support.
Where Apigenin Research Stands Today
Today apigenin sits at an interesting crossroads: a compound with a long history of dietary consumption, with chamomile in tea amounts considered likely safe by NIH’s NCCIH although allergic reactions occur in some people [5], a substantial and growing body of mechanistic preclinical research, and a comparatively thin base of rigorous human clinical trials. Understanding that history helps put current marketing claims in perspective, neither dismissing a compound with real scientific interest behind it, nor treating preliminary lab findings as settled human outcomes.
Frequently Asked Questions
Where does the word “apigenin” come from?
The name derives from Apium, the genus name for parsley and celery, reflecting the plants from which flavone chemists first characterized related compounds.
Is chamomile tea a meaningful source of apigenin?
Chamomile tea does contain apigenin, mostly as apigenin glycosides rather than free apigenin, and in healthy men urinary excretion after chamomile tea equalled 34% of the apigenin glucoside intake; no per-cup amount is established in the published research reviewed [6][7].
When did scientists start studying apigenin for cancer research?
Interest accelerated from the 1990s onward as part of a broader wave of research into dietary flavonoids and cancer cell biology, and it remains an active preclinical research area today.
Is apigenin a new discovery?
No, the compound itself was characterized in the 19th century. What is newer is the pharmacological research explaining how it interacts with the body, and its recent popularity as a supplement ingredient.
These statements have not been evaluated by the FDA. Apigenin is not intended to diagnose, treat, cure, or prevent any disease. Talk to a qualified healthcare provider before starting any new supplement, especially if you take prescription medication.
References
- McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phytotherapy Research (2007). PMID 16628544
- Viola H, Wasowski C, Levi de Stein M, Wolfman C, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica (1995). PMID 7617761
- Avallone R, Zanoli P, Puia G, Kleinschnitz M, et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology (2000). PMID 10751547
- Campbell EL et al. The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical pharmacology (2004). PMID 15451406
- National Center for Complementary and Integrative Health (NIH) Chamomile: Usefulness and Safety. National Center for Complementary and Integrative Health (NIH) source
- Corina Danciu et al. Botanical Therapeutics: Phytochemical Screening and Biological Assessment of Chamomile, Parsley and Celery Extracts against A375 Human Melanoma and Dendritic Cells. International Journal of Molecular Sciences (2018). PMID 30453564
- Borges G et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free radical biology & medicine (2022). PMID 35452808
- Sogand Saadatmand et al. The Effect of Oral Chamomile on Anxiety: A Systematic Review of Clinical Trials. Clinical Nutrition Research (2024). PMID 38784853
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
